Table 2.
Consensus ranking comprising of MTT, MitoSOX, and LDH cytotoxicity assay.
| Drug name | Cyto toxicity ranking | |||
|---|---|---|---|---|
| MTT | MitoSOX | LDH | Ave. | |
| Control | 4 | 4 | 1 | 3.0 |
| Ingenol | 1 | 7 | 6 | 4.7 |
| Sulforaphane | 7 | 5 | 7 | 6.3 |
| Tanespimycin | 8 | 1 | 10 | 6.3 |
| Idarubicin | 3 | 15 | 5 | 7.7 |
| CD-437 | 2 | 9 | 15 | 8.7 |
| PIK-75 | 11 | 11 | 4 | 8.7 |
| Gemcitabine | 9 | 14 | 3 | 8.7 |
| Acetylcysteine | 5 | 6 | 16 | 9.0 |
| Tretinoin | 6 | 3 | 18 | 9.0 |
| Bortezomib | 10 | 10 | 8 | 9.3 |
| NVP-BEZ235 | 15 | 2 | 13 | 10.0 |
| SN-38 | 14 | 16 | 2 | 10.7 |
| NVP-AUY922 | 16 | 12 | 9 | 12.3 |
| Parbendazole | 13 | 13 | 11 | 12.3 |
| Amifostine | 18 | 8 | 14 | 13.3 |
| YM-155 | 12 | 17 | 12 | 13.7 |
| FK-866 | 17 | 18 | 17 | 17.3 |
Each value means ranking of low toxicity (i.e., high number means high toxicity). Drugs are sorted based on the average ranking over 3 assays.